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RESEARCH
Lactococcus lactis provides an efficient 
platform for production of disulfide-rich 
recombinant proteins from Plasmodium 
falciparum
Susheel K. Singh1,2,3, Régis Wendpayangde Tiendrebeogo1,2,3, Bishwanath Kumar Chourasia1,2,3, 
Ikhlaq Hussain Kana1,2,3, Subhash Singh4 and Michael Theisen1,2,3*
Abstract 
Background: The production of recombinant proteins with proper conformation, appropriate post-translational 
modifications in an easily scalable and cost-effective system is challenging. Lactococcus lactis has recently been identi-
fied as an efficient Gram positive cell factory for the production of recombinant protein. We and others have used 
this expression host for the production of selected malaria vaccine candidates. The safety of this production system 
has been confirmed in multiple clinical trials. Here we have explored L. lactis cell factories for the production of 31 
representative Plasmodium falciparum antigens with varying sizes (ranging from 9 to 90 kDa) and varying degree of 
predicted structural complexities including eleven antigens with multiple predicted structural disulfide bonds, those 
which are considered difficult-to-produce proteins.
Results: Of the 31 recombinant constructs attempted in the L. lactis expression system, the initial expression effi-
ciency was 55% with 17 out of 31 recombinant gene constructs producing high levels of secreted recombinant pro-
tein. The majority of the constructs which failed to produce a recombinant protein were found to consist of multiple 
intra-molecular disulfide-bonds. We found that these disulfide-rich constructs could be produced in high yields when 
genetically fused to an intrinsically disorder protein domain (GLURP-R0). By exploiting the distinct biophysical and 
structural properties of the intrinsically disordered protein region we developed a simple heat-based strategy for fast 
purification of the disulfide-rich protein domains in yields ranging from 1 to 40 mg/l.
Conclusions: A novel procedure for the production and purification  of disulfide-rich recombinant proteins in L. lactis 
is described.
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Background
Protein production is often the limiting factor in research 
and development of vaccines, sero-diagnostic tools, and 
immuno-assays. The yield, purity and cost of produc-
tion are some of the important parameters which deter-
mine the choice of expression system for recombinant 
protein production. There is no single system, which can 
accommodate all recombinant proteins, and if success-
ful, expression yields vary by orders of magnitudes due 
to biophysical and structural properties of the recombi-
nant proteins. Of the different proteins, the production 
of homogenously folded disulfide bonded proteins have 
been particularly challenging [1, 2]. The lactic acid bac-
teria Lactococcus lactis has gained importance as a host 
for heterologous protein expression [3–7] because (1) 
it can export the recombinant protein into the culture 
supernatant from where it can be readily purified, (2) 
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it is a Gram positive bacteria which does not produce 
endotoxins, (3) unwanted glycosylation of proteins has 
not been described, and (4) it is ‘generally recognized as 
safe’ (GRAS). The L. lactis expression system is compat-
ible with large-scale upstream and downstream processes 
and therefore provides a low cost production system. The 
safety of this expression system has been demonstrated in 
humans (reviewed in [8, 9]). Recently, we have reported 
use of L. lactis for successful production of recombinant 
Pfs48/45, a disulfide-rich malaria transmission blocking 
vaccine candidate from Plasmodium falciparum, which 
has been difficult to produce as recombinant protein with 
correct conformation using a variety of other prokary-
otic as well as eukaryotic recombinant protein expression 
systems.
In this study we have further demonstrated the suit-
ability of L. lactis for expression and purification of a 
panel of 31 recombinant proteins from 25 distinct anti-
gens of P. falciparum (non-overlapping sub-domains 
from some antigens were expressed separately to study 
their distinct antigenic properties) as several of which 
consist multiple structural disulfide bonds. Proper 
disulfide bond formation of the recombinant antigens is 
essential for not only the native structure and its anti-
genic property but also for inducing appropriate innate 
and adaptive immune responses. The antigens selected 
in this study are localized in diverse sub-cellular com-
partments of the merozoite, the transient extracellular 
stage of the asexual blood stage of P. falciparum, which 
is highly specialized for erythrocyte invasion [10, 11]. 
These include the integral merozoite membrane pro-
teins, the associated peripheral surface proteins and 
proteins secreted from the various secretory organelles 
such as the micronemes, rophtries and the dense gran-
ules which are understood to form functional com-
plexes with merozoite surface proteins [12]. Together 
these merozoite surface protein complexes play impor-
tant roles in erythrocyte invasion and several of them 
have been identified as putative targets of protective 
immunity against malaria [13]. The panel of malaria 
antigens selected in this present study covers a variety 
of protein structural complexities, ranging from pro-
teins predicted to have a highly disordered structure 
to those consisting of multiple (2–75) cysteine residues 
predicted to form structural disulfide bonds determin-
ing the overall secondary and tertiary structure of the 
respective proteins. The panel of malaria antigens con-
sists of merozoite antigens which are targets of (1) natu-
rally acquired immunity, (2) functional antibodies, and 
(3) include both variable and conserved regions of the 
respective antigens. We show that L. lactis is an efficient 
system for expression of recombinant malaria antigens 
with a variety of protein structural complexities.
Results
Protein expression
A panel of P. falciparum proteins targeted by naturally 
acquired immune responses was produced as C-termi-
nally His-tagged proteins in L. lactis MG1363 (Fig. 1a(i)). 
Sub-domains of some malaria antigens representing the 
variable and conserved regions (such as from MSP2 to 
MSP3) were expressed as separate recombinant proteins 
to allow detection of both allele-specific and cross-reac-
tive antibodies (Table 1). The success of recombinant pro-
tein production from the respective L. lactis clone was 
determined (as Low, Medium or High) as per the yield of 
the secreted recombinant protein purified from a batch 
fermentation of 1 l. We observed an overall efficiency of 
55% with 17 out of 31 recombinant clones producing a 
secreted recombinant protein as detected by SDS-PAGE 
and Western Blot analysis (Table  1). The success rate 
was much higher (80%) for recombinant proteins which 
lacked cysteine residues (expression was detected for 16 
out of 20 such recombinant proteins). However, the suc-
cess rate was lower (9%) for those recombinant proteins 
containing two or more cysteine residues (expression 
was detected for only 1 out of 11 recombinant proteins). 
In general, expression constructs which produced high 
yields of recombinant proteins were low in cysteine 
residues and relatively unstructured (Additional file 1a). 
In contrast, neither the iso-electric point (pI) nor the 
molecular weight of the cloned expression construct 
seemed to affect its expression level in L. lactis (Addi-
tional file  1b). We therefore speculated that increasing 
the overall disorder score of the difficult-to-express pro-
teins by creating a fusion protein with an unstructured 
protein domain might enhance the yield of the desired 
recombinant protein. Accordingly, constructs which 
failed to produce a recombinant protein were geneti-
cally linked to an unstructured carrier protein (the R0 
sub-domain of the GLURP antigen) (Fig.  1a(ii)). A TEV 
protease cleavage site was inserted in the fusion-junction 
to allow removal of the R0 carrier protein. Twelve out of 
fourteen fusion recombinant constructs thus designed, 
showed higher expression levels compared to the respec-
tive target proteins expressed without fusion with the 
disordered carrier protein (Fig. 1a). Two constructs with 
large number of cysteine residues and highly complex 
predicted secondary structure (EBA140RII and RIPR 
containing 23 and 75 cysteine residues, respectively) did 
not show improvement in their expression levels despite 
their fusion with the carrier protein.
Protein purification
A simple workflow was developed consisting of batch-
fermentation and a 2-step downstream purification pro-
cess. Recombinant proteins from L. lactis expressing 
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clones were secreted in the culture medium and har-
vested by separation of cellular biomass through cen-
trifugation and affinity purified through the His-tag 
using HisTrap HP-column. Upon elution the fractions 
containing the recombinant protein were collectively 
subjected to a polishing step using ion-exchange chro-
matography to further remove contaminating host-cell-
protein (HCP). Using this approach a highly purified 
recombinant protein was obtained as exemplified with 
recombinant  cMSP33D7 (Fig.  1b). Recombinant proteins 
expressed with R0-fusion partner were harvested from 
the clarified culture medium using the same proce-
dure as described above and exemplified with recombi-
nant R0-MSPDBL2 (Fig. 1c). The affinity purified fusion 
protein (Fig.  1c, lane 2) was cleaved with the TEV pro-
tease (Fig. 1c, lane 3) before being purified further with 
ion-exchange chromatography column (Table 1) to sepa-
rate HCP, TEV, and the R0-fusion partner (Fig. 1c, lane 4) 
from the target recombinant protein (Fig. 1c, lane 5). The 
identity and purity of the target protein was confirmed 
at each step by immune blotting with antibodies against 
the His-tag and R0 to demonstrate removal of the carrier 
protein (Fig. 1b, c).
GLURP stabilizes structural domains against thermal 
denaturation
The GLURP-R0 region is highly disordered as predicted 
by the IUPred software and is characterized to have low 
hydrophobicity and high net charge (Table 1). It migrates 
on SDS-PAGE with an apparent molecular mass more 
than twofold higher than its predicted molecular mass. 
Disordered proteins are often heat-resistant [14] and 
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Fig. 1 Expression and Purification of target recombinant proteins in L. lactis. a Left panel: Schematic representation for cloning and expression 
of target recombinant proteins from P. falciparum antigens without (i) and with (ii) carrier fusion protein; Right panel: Classification of the target 
recombinant proteins based on their cysteine content (constructs containing two or more cysteine residues are classified as cysteine-rich proteins) 
and the overall success rates for production of target recombinant proteins by the respective L. lactis expression clones using strategy (i) or (ii). 
b Expression and purification of recombinant  cMSP33D7 (a representative recombinant protein which does not contain cysteine residues and 
expressed successfully in L. lactis without carrier fusion protein); Left panel: Coomassie blue-stained non-reducing SDS-PAGE analysis showing 
purification of recombinant  cMSP33D7protein secreted in L. lactis culture supernatant; Lane 1: raw culture supernatant, lane 2:  Ni+-NTA purified 
 cMSP33D7; lane 3: Ion-exchange purified  cMSP33D7; Right panel: Western Blot analysis of recombinant  cMSP33D7 using anti-His antibody. c Expression 
and purification of recombinant R0-MSPDBL2 (a representative cysteine-rich recombinant protein and which was expressed successfully in L. lactis 
with GLURP-R0 as a carrier fusion protein); Left panel: Coomassie blue-stained non-reducing SDS-PAGE analysis showing purification of recombinant 
R0-MSPDBL2 protein secreted in L. lactis culture supernatant; Middle panel: Western blot analysis of recombinant R0-MSPDBL2 using anti-His 
antibody; and Right panel: Western blot analysis of recombinant R0-MSPDBL2 using anti-GLURP-R0 antibody; Lane 1: raw culture supernatant; 
lane 2: Affinity purified R0-MSPDBL2 recombinant protein; lane 3: TEV cleavage of recombinant R0-MSPDBL2 and SDS-PAGE separation of R0 and 
MSPDBL2 fragments; Lane 4: Ion-exchange chromatography separates cleaved R0 carrier protein after TEV protease cleavage and Lane 5: Purified 
recombinant MSPDBL2 obtained after TEV cleavage and ion-exchange chromatography. The arrow-heads indicate positions of  cMSP33D7 and 
MSPDBL2 recombinant proteins in respective panels. Numbers shown on the left hand side of the gel pictures represent positions of protein 
molecular weight markers in kDa
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since boiling has been used as a strategy to purify simi-
larly disordered recombinant epsin 1 and AP180 [15], 
we speculated that GLURP-R0 might stabilize its fusion 
partners against thermal denaturation. In a first experi-
ment, we cultured the MSPDBL2 construct without 
(Fig.  2a) and with (Fig.  2b) a R0-fusion partner. Boiling 
of culture supernatants from the batch fermentation of 
recombinant clones expressing R0-fusion constructs and 
its immediate cooling in an ice-bath resulted in the dena-
turation of > 80% of the HCP, which was subsequently 
removed by centrifugation (Fig. 2a, b, lane 2). The MSP-
DBL2 recombinant protein did not resist heat-treatment 
(Fig. 2a, lane 2) whereas the R0-MSPDBL2 fusion protein 
remained in solution under these conditions (Fig.  2b, 
lane 2). The supernatant containing R0-MSPDBL2 was 
incubated with the TEV protease (Fig. 2b, lane 3) and the 
resulting mixture was subjected to purification through 
ion-exchange chromatography column to separate TEV-
protease, R0-fusion partner and HCP (Fig.  2b, lane 4) 
from the target protein (Fig. 2b, lane 5). The integrity of 
the resulting MSPDBL2-domain was examined by SE-
HPLC and ELISA. For comparison, recombinant MSP-
DBL2 purified without heat-treatment was included in 
the analysis. The two MSPDBL2 recombinant proteins 
migrated with similar retention times of 5.54  min by 
SE-HPLC (Fig.  2c) suggesting that heat treatment did 
not affect protein-stability and multimerization. The 
two MSPDBL2 protein preparations also showed similar 
antigenicity profiles against sera from malaria-immune 
individuals suggesting that the overall protein structure 
of the cysteine-rich DBL2 domain is unaffected by the 
heat-treatment (Fig. 2d). Next, we applied the same heat-
treatment and purification procedure to the remaining 
nine R0-fusion proteins (Table 1).
Comparative assessment of purified recombinant 
merozoite proteins
Most of the purified cysteine-rich recombinant proteins 
migrated as a single band by SDS-PAGE under non-
reducing conditions with apparent molecular weights, 
which are in agreement with those predicted from the 
deduced amino acid sequence (Fig.  3). The addition of 
a reducing agent resulted in a band shift in the mobil-
ity of these recombinant proteins on SDS-PAGE dem-
onstrating that these recombinant proteins consist of 
disulfide-bonds. Disulfide-bonding in these protein 
preparations was further confirmed by demonstrating no 
or very low levels (< 1%) of free thiol under native con-
dition. SDS-PAGE analysis also showed that many of the 
non-disulfide bonded proteins and particularly those 
with high predicted disorder scores migrated with much 
higher apparent molecular weights than their respective 
predicted MWs (Additional file 2). As expected, a strong 
correlation between anomalous migration as observed 
by SDS-PAGE and disorder score (Additional file  3, r 
0.7554) was observed.
The overall structure of the purified recombinant pro-
teins was also examined by assessing their antigenicity in 
a multiplex assay (MPA). All antigens were recognized 
by naturally acquired antibodies in plasma from hyper 
immune Liberian blood donors (Fig. 4).
Discussion
Lactic acid bacteria have a long history of use in the pro-
duction of fermented foods. More recently, they have 
also gained importance as microbial cell factories for the 
production of pharmaceuticals [8, 9]. Development of 
new vaccines and sero-diagnostic tools constantly pose 
challenges to the identification of convenient and potent 
expression systems for recombinant protein production. 
Here, we have shown that the L. lactis expression systems 
is ideal for the production of malaria antigens because it 
(i) accommodates cysteine-rich proteins (ii) offers a scal-
able fermentation process (iii) allows secretion of the 
recombinant protein into the culture medium thereby 
simplifying the purification process, and (iv) exhibits sim-
ilar codon bias as P. falciparum and therefore does not 
require codon optimization prior to protein expression.
Plasmodium falciparum merozoite antigens have previ-
ously been produced in E. coli [16], wheat germ cell–free 
expression system [17] and HEK293 cells [18]. Whereas 
each of these systems proved successful for some anti-
gens, they also present distinct challenges with respect to 
producing correct post-translational modifications which 
usually determine the quality and activity of the target 
recombinant protein. In eukaryotes such as P. falciparum, 
the oxidizing environment of the endoplasmic reticulum 
(ER) provides a milieu for disulfide bond formation [19]. 
Eukaryotic expression systems may potentially form the 
native disulfide bonds. In contrast, prokaryotic organ-
isms lack the sophisticated ER machinery of and show 
considerable diversity in their mechanisms and capacity 
for formation of protein disulfide bonds [20]. Amongst 
prokaryotes, E. coli has long been the first choice for 
recombinant protein production potentially giving very 
high yields. However, expression of disulfide-bonded 
proteins in E. coli remains challenging and use of differ-
ent E. coli strains have been proposed to overcome some 
of these difficulties [2]. Though the mechanisms which 
control the formation of disulfide bonds in L. lactis are 
uncharacterized, this system has proved an efficient 
host for the production of disulfide bonded fragments of 
Pfs48/45 [21–25].
Glycosylation is another common protein post-trans-
lational modification likely to affect the antigenic prop-
erties of the recombinant protein depending on the host 
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cell system used for its expression [26]. Since, most of the 
P. falciparum antigens are non-glycosylated, using eukar-
yotic expression systems which perform host-specific gly-
cosylation, may compromise essential epitopes of these 
antigens. To avoid glycosylation these eukaryotic sys-
tems necessitate mutation of N-linked glycosylation sites, 
which in turn might alter functionality [27] and possibly 
antigenicity and immunogenicity of the recombinant 
protein. In contrast, L. lactis does not perform unwanted 
glycosylation and has proven useful for the production 
of a disulfide-bonded malaria protein [21]. In general, 
we feel that L. lactis has following advantages over E. 
coli for expression of malaria recombinant proteins: (1) 
Codon-optimization of the recombinant malaria gene 
is not required for obtaining successful expression in L. 
lactis; (2) Recombinant protein is secreted in the L. lactis 
culture supernatant making the down-stream processing 
much easier and less-expensive; and (3) There is no lipo-
polysaccharide contamination in L. lactis expression.
In the present study, we have produced a panel of mer-
ozoite antigens consisting of proteins with and without 
disulfide bonds. We found an overall success rate of 55% 
but it was also evident that the success rate for disulfide-
bonded proteins was lower than that for cysteine-poor 
proteins (9% vs. 80%). In general, the production yield of 
relatively disordered protein fragments was higher than 
that of ordered protein regions. The exact reason for this 
is unknown but it may be speculated that higher solubil-
ity, increased stability, or a more efficient transportation 
across the cell membrane may play a role. Though the 
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underlying mechanism is not clear, addition of an intrin-
sically disordered protein fragment increased the over-
all yield of these difficult-to-express protein fragments. 
Eight out of 10 disulfide bonded proteins produced high 
levels of recombinant protein when fused to the GLURP 
R0-region.
GLURP belongs to a group of proteins lacking ordered 
structure [28, 29], known as intrinsically disordered pro-
teins (IDP). These proteins exist without a well-defined 
folded structure, having a highly biased amino acid 
composition with no cysteine and aromatic residues, an 
overall low hydrophobicity level, and an extremely high 
content of charged residues (Reviewed in [14, 30, 31]). 
The relatively, low content of hydrophobic amino acid 
residues may explain the anomalous migration by SDS-
PAGE observed in our study. A deficiency in hydrophobic 
amino acid residues may result in less binding of SDS [32, 
33], thereby slowing migration and therefore resulting in 
an apparent overestimation of the molecular mass of the 
recombinant protein through SDS-PAGE analysis.
In the present study we argue that these peculiarities 
of the amino acid sequences of the intrinsically disorder 
protein domain of the fusion proteins increased the over-
all protein expression efficiencies by increasing solubility, 
resistance to aggregation and possibly by facilitating the 
translocation of otherwise tightly folded proteins across 
the cell membrane. The lack of a stable globular structure 
provides IDP with several extraordinary features includ-
ing the ability to be unharmed by prolonged heat treat-
ment ([31] and references therein). We have for the first 
time exploited this feature to provide a highly structured 
protein with the same indifference to heat treatment. This 
ability of the IDP was first explored by creating a protein 
fusion with the disulfide-bonded MSPDBL2. Our results 
clearly demonstrate that GLURP-R0 protects the integrity 
of the MSPDBL2 domain from boiling. The MSPDBL2 
domain purified by heat-treatment and by conventional 
purified showed similar HPLC and antigenicity profiles. 
In contrast, more than 80% of the HCP was eliminated 
by this heat treatment step possibly because of a low con-
tent of intrinsically disordered proteins in L. lactis culture 
supernatants. The applicability of this method was further 
examined by creating protein fusions between GLURP-
R0 and nine other disulfide-rich merozoite antigens. All 
fusion proteins were heat stable and the resulting disulfide-
rich merozoite antigens were strongly recognized by natu-
rally acquired P. falciparum antibodies with levels and 
prevalence of specific IgG antibodies which were similar to 
those observed with malaria antigens produced in several 
other systems [17, 34, 35]. Whether this novel purification 
strategy might be applied to other disulfide-rich proteins 
of non-malarial origin remains to be investigated.
In conclusion, we have demonstrated that L. lactis is 
an efficient host for production of P. falciparum antigens. 
We have specifically expanded the toolbox to include a 
novel procedure based on fusion with IDP-carrier protein 
and successful heat-based purification for production of 
disulfide-rich proteins. The efficiency of this technique 
suggests that it could replace the capturing step by IMAC 
thus, simplifying and accelerating the purification of 
recombinant proteins. This approach could also facilitate 
production of affinity-tag free functional recombinant 
proteins at industrial-scale for clinical applications.
Methods
Preparation of constructs
Target DNA sequences from selected P. falciparum genes 
(Table  1) were amplified by PCR using gene specific 
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primers. For Sera53D7 and MSP2FC27 we used respective 
synthetic genes  (GeneArt® Life Technologies, Germany). 
All constructs without the GLURP-R0 carrier were 
cloned into the BglII restriction site of pSS1 [22]. GLURP 
fusion proteins were constructed by cloning the target 
gene into the BglII restriction site of pSS2 [22]. The tar-
get gene was amplified with a forward primer containing 
the DNA sequence encoding for a TEV protease cleavage 
site (ENLYFQG) thereby creating a protein fusion with 
the TEV site in the fusion junction. All constructs were 
verified by sequencing and subsequently transformed 
into Lactococcus lactis MG1363 by electroporation as 
described [22].
Screening and fermentation
Five-ten colonies from each transformation were grown 
overnight at 30  °C in 5  ml LAB medium supplemented 
with 4% glycerol–phosphate, 5% glucose and 5  μg/ml 
erythromycin. Culture supernatants were clarified by cen-
trifugation at 9000g for 20  min and protein expression 
levels were assessed in the culture supernatants by ELISA 
using HRP-conjugated anti-His antibody (MACS, Miltenyi 
biotech, Germany) and by SDS-PAGE. L. lactis MG1363 
harboring expression constructs was grown in a 1 l stirred 
bioreactors for 15 h at 30 °C [23]. Cells were removed by 
centrifugation at 9000 rpm for 30 min and the raw culture 
supernatant was clarified by filtration. Culture-filtrates 
were either used immediately or stored at − 20 °C.
Purification of proteins expressed without R0‑fusion 
partner
Culture-filtrates were concentrated fivefold and diafil-
trated in quick stand system (GE Healthcare, Sweden) 
against Tris-buffered saline (TBS) pH 8.0 supplemented 
with 10  mM imidazole. Recombinant protein was cap-
tured from the clarified culture supernatant on a 5  ml 
HisTrap HP column (GE Healthcare, Sweden). Bound 
protein was eluted with TBS plus 500 mM imidazole at a 
flow rate of 4 ml/min and fractions containing the desired 
protein were pooled and diluted tenfold in 50  mM Tris 
buffer before loading on the 5  ml HiTrap Q HP or the 
5  ml HiTrap SP HP columns (GE Healthcare, Sweden). 
Bound protein was eluted through gradient elution in 
50 mM Tris containing 0–1 M NaCl. Fractions contain-
ing the recombinant protein were pooled and buffer 
exchanged against 50 mM Tris, 300 mM NaCl and 1 mM 
EDTA, pH 8.0.
Purification of recombinant proteins expressed 
with R0‑fusion partner
Recombinant fusion proteins were expressed and affin-
ity purified as described above. The purified fusion 
protein was digested for 16  h at room temperature 
with the TEV protease [36], diluted tenfold with 
50 mM Tris buffer and loaded on to the ion-exchange 
chromatography column (Table  1). Bound protein 
was eluted gradient elution in 50  mM Tris contain-
ing 0–1 M NaCl thereby separating the target protein 
from the GLURP fusion partner and the TEV protease. 
Purified recombinant protein was concentrated by a 
VIVA spin column 10 kDa cutoffs (Sartorius, UK), and 
stored in TBS plus 1  mM EDTA at − 80  °C until use. 
Protein concentration was determined by the BCA 
protein assay (Thermo Fisher Scientific). Purity of tar-
get recombinant proteins were monitored using 4–12% 
Tris-tricine SDS-PAGE gels. Western blotting was 
performed using HRP-conjugated anti-His and anti-
GLURP-R0 antibodies.
Protein purification by boiling
Clarified culture-filtrates were concentrated fivefold and 
incubated in a boiling water-bath for 10  min followed 
by immediate cooling in an ice-bath. Host cell proteins 
(HCP) were removed by centrifugation at 30,000  rpm 
for 15  min at 4  °C and the supernatant containing the 
GLURP-R0 fusion protein was buffer exchanged against 
TBS and incubated with the TEV protease for 16  h at 
room temperature and the target protein was purified as 
described above.
SE‑HPLC and free thiol determination
Analytical size exclusion high-performance liquid chroma-
tography (SE-HPLC) of purified proteins was performed 
using an Agilent 1100 Series HPLC System (Agilent 
Technologies, USA) equipped with a Agilent advance Bio 
SEC 300  Å, 2.7  μm, 4.6 × 300  mm SEC column, (Agilent 
Technologies, GB) as per the manufacturer’s instructions. 
Briefly, five hundred pmol of protein was loaded on the 
SEC column and eluted with a 0.350 ml/min flow of elu-
tion buffer (phosphate buffer) at room temperature. Stand-
ard proteins from Sigma Aldrich were also run using same 
the conditions mentioned above for sizing of the purified 
recombinant proteins. The absorbance was measured at 
280  nm and chromatographic peaks were integrated by 
HPLC ChemStation (Agilent Technologies, CA, US). The 
amount of free cysteine residues was measured using Ell-
man’s Reagent (Thermo fisher scientific, USA) following 
the manufacturer’s instructions. A standard curve was 
constructed using known concentrations of free cysteine 
(Sigma-Aldrich, USA).
Enzyme linked immunosorbent assay (ELISA) and Multiplex 
analysis
ELISA was performed as described elsewhere [37, 38]. 
The coating concentration of recombinant protein was 
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1 μg/ml. Serum samples were used from hyperimmune 
adults (malaria infected though clinically healthy male 
blood donors) living in an area in Liberia where malaria 
is holoendemic, or from Danish donors never exposed 
to malaria infection [39]. Antigenicity of the puri-
fied recombinant proteins was assessed in a multiplex 
Luminex assay as described elsewhere [40] with minor 
modifications. Briefly, approximately 1250 microspheres 
from each of the 26 antigens coupled bead regions were 
mixed in three separate mixtures. Plex 1 contained: 
GLURP-R0, GLURP-R2,  cMSP33D7,  nMSP3K1, MSP3.7, 
MSP6, Pf38,  MSP119k, and BSA; Plex 2 contained, MSP-
DBL2, SERA5,  MSP23D7, Pf41, Pf12, MSP3.3,  nMSP33D7 
and BSA; and Plex 3 contained MSPDBL1,  MSP2FC27, 
GAMA, RAMA,  MSPDBL1Leu, PfRH2-2030, PfRH2a, 
PfRH2b, RALP-1, RON4, EBA140RIII-V and BSA. 
EBA140 RII, RIPR, SUB2, RON2 and PfRh4.2 could 
not be included in the MPA due to either low protein 
production or unavailability of recombinant proteins 
during plex preparation. 50  μl of each Plex mixture 
was added to a 96-well filter micro titer plate (MSBVS 
1210, Millipore). For positive and negative controls, a 
pool of plasma from five hyperimmune Liberian donors 
and a pool of plasma from eight Danish donors tested 
at 1:2000 dilutions were used. Fifty-four hyperim-
mune Liberian and 100 Danish sera samples are tested 
in singlet at 1:1000 dilution by adding 100  μl/well and 
incubated with shaking for 2 h in the dark. After three 
washes, bound IgG was detected with PE-labeled goat 
anti-human IgG (Jackson Immuno Research Labora-
tories, West Grove, PA). Levels of specific antibodies 
against each antigens were nearly identical either deter-
mined by the multiplex assay (all beads in each plex) 
or by single-antigen assay (single bead/antigen), dem-
onstrating that none of the antigens competed for or 
bound cross-reactive IgG antibodies (data not shown).
Disorder prediction
IUPred software was used for the prediction of protein 
disorder [41]. For analysis of protein disorder, we esti-
mated a disorder score for each recombinant protein by 
calculating the percentage of residues with a disorder 
score above 0.7.
Statistical analysis
The Mann–Whitney rank sum test was used for analyz-
ing differences between groups. P < 0.05 was considered 
to be statistically significant.
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